D2 Insights & Perspectives 
Image by Darren Halstead

Analysis of the HHS Proposed Rule - Drug Rebates

Proposed rule to eliminate pharmaceutical rebates raises challenging questions                                                                                                        

Dean Erhardt, MBA

Full frame of colorful antimicrobial cap

McKesson's New Deal with the VA 

Understanding wholesale negative distribution fees and what the latest arrangement between McKesson and the VA will mean for drug manufacturers

John Brannan, MBA

Top 5 Guidelines to Federal Market Success in 2020

What pharma needs to know to operate effectively in changing Federal market conditions                                                                                                                                                                         

COVID-19 Communication Tool

HIPPA compliant group text messaging from pharmacy to patient     

 

Dean Erhardt, MBA

for specialty pharmacy section.jpg

Specialty Pharmacy Accreditation

Accreditation status is both an entry ticket and a competitive measure for specialty pharmacies to attract manufacturers                                                                                                                                        

Quintin Jessee, RPh

dd.png

Outcomes-Based Contracting

D2's talks implications and potential benefits of outcomes-based contracts                                                                                                                                                                                                                                                                                             

vb.png

Pharmaceutical Traceability 

D2's Bob Glasgow talks modernization of the US drug supply chain

Bob Glasgow, MBA

gg.png

Ripple Effect of Drug Pricing

D2's Dean Erhardt talks spillover effects of high-priced drugs

Dean Erhardt, MBA

sdfsdfsdfsdfsdfsdf.JPG

Succession Planning in Healthcare

D2's Cheryl Nagowski talks 7 tips for healthcare exec succession planning

tech.jpg

Using Tech to Better Serve Patients

D2's CEO Dean Erhardt talks how to leverage new technologies to better serve patient needs                                        

Dean Erhardt, MBA

Image by Jonathan Roger

A Context for Drug Pricing

Branded prescription drug spend - a basic framework                                                                                                                              

Computer Keyboard - Online Prescriptions

Specialty Pharmacy Accreditation

Changes Coming in Specialty Pharmacy Accreditation                                                                                                              

Quintin Jessee, RPh

Image by Tbel Abuseridze

Specialty Pharmacy Data Standards

Exploring the triple-aim of healthcare advancement

Kirby Eng, RPh

tt.PNG

DoD's New Market Structure

Part II of a optimization series on pharmaceutical industry effectiveness in the Department of Defense 

Col(r) David Bobb, RPh, JD

Multiple white tablets of drugs or vitam

Challenges of Drug Pricing

D2's talks the future of Federal pricing controls under the current administration

Annotation 2020-01-20 160051.jpg

FDA's Plans to Boost Competition

What the FDA's Plans to Boost Drug Competition Could Mean for Pharma                                                                                                                     

Dean Erhardt, MBA

GettyImages-1097997064.jpg

Better ROI in Managed Markets

Optimizing investments in Federal markets                                                                                                                                                  

GettyImages-1134245411.jpg

Specialty Pharmacy - URAC Standards

Preparation for URAC accreditation requires careful attention to four specific standards                                           

Quintin Jessee, RPh

For Friends & Client's of D2

  • Circumstances Leading to the Rise of VBCs

  • Current VBC Arrangements

  • VBC in Current Regulatory Environment

  • Future State - Changes that Could Foster VBCs

White Paper.jpg

D2 St. Louis (HQ)

400 Chesterfield Center Suite 400

Chesterfield, MO 63017

D2 Boston

100 Summit Drive

Burlington, MA 01803

  • Facebook
  • Twitter
  • LinkedIn

© 2020 D2 Pharma Consulting LLC. All Rights Reserved